%0 Journal Article
%A Liu, Yibin
%A Keib, Anna
%A Neuber, Brigitte
%A Wang, Lei
%A Riemer, Angelika
%A Bonsack, Maria
%A Hückelhoven-Krauss, Angela
%A Schmitt, Anita
%A Müller-Tidow, Carsten
%A Schmitt, Michael
%T Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma.
%J International journal of molecular sciences
%V 24
%N 3
%@ 1422-0067
%C Basel
%I Molecular Diversity Preservation International
%M DKFZ-2023-00333
%P 1943
%D 2023
%X The transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal prognosis of relapsed/refractory GBM patients. Immunotherapy is considered a promising strategy against GBM, but there is a fervent need for better immunotargets in GBM. To this end, we performed an in silico prediction study on SOX11, which primarily yielded ten promising HLA-A*0201-restricted peptides derived from SOX11. We defined a novel peptide FMACSPVAL, which had the highest score according to in silico prediction (6.02 nM by NetMHC-4.0) and showed an exquisite binding affinity to the HLA-A*0201 molecule in the peptide-binding assays. In the IFN-γ ELISPOT assays, FMACSPVAL demonstrated a high efficiency for generating SOX11-specific CD8+ T cells. Nine out of thirty-two healthy donors showed a positive response to SOX11, as assessed by the ELISPOT assays. Therefore, this novel antigen peptide epitope seems to be promising as a target for T cell-based immunotherapy in GBM. The adoptive transfer of in vitro elicited SOX11-specific CD8+ T cells constitutes a potential approach for the treatment of GBM patients.
%K HLA-A*0201 (Other)
%K SOX11 (Other)
%K glioma (Other)
%K immunotherapy (Other)
%K tumor-associated antigen (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36768267
%R 10.3390/ijms24031943
%U https://inrepo02.dkfz.de/record/267555